Pharma lead generation works when you sell to a buying committee, not a person: R&D, clinical operations, procurement, quality and IT all have a say. The teams that win build accounts from public signals (pipelines, trials, funding, site expansions), reach each committee member with a role-specific message, and stay compliant with GDPR from the first touch. This playbook covers who buys, where to find them, and how to start the conversation.

TL;DR

• "Pharma lead generation" here means B2B vendors selling to pharma and biotech: CROs, CDMOs, lab and equipment suppliers, software and data vendors.

• Public signals beat bought lists. Clinical trial registries, funding news and facility announcements tell you who has a need right now.

• Map the committee early. A scientist can champion you, but procurement and quality decide.

• In the EU, B2B outreach to named people needs a documented legitimate interest and an easy opt-out.

Why pharma is worth the effort

The market is large and still investing. The European research-based pharmaceutical industry spent an estimated €55 billion on R&D in 2024 and employed around 950,000 people, according to EFPIA's Pharmaceutical Industry in Figures 2025. Every euro of that R&D spend flows through suppliers: trial services, manufacturing capacity, lab equipment, data platforms and software.

The catch is that pharma buys slowly and carefully. Regulated processes, supplier qualification and validation requirements mean the gap between a first meeting and a signed contract is usually measured in quarters, not weeks. Lead generation has to be built for that cycle.

Who actually buys: the pharma buying committee

Most deals involve several functions. The table maps who they are and what opens each one.

A few patterns hold across most accounts:

• The champion is rarely the signer. A head of discovery or a clinical operations lead will pull you in. Procurement, quality and finance sign.

• Quality can veto late. If your offer touches GxP processes, bring quality assurance in before the proposal, not after.

• IT and data leads now join early. Any software, data or AI offer triggers validation and security reviews.

Where to find pharma accounts with a real need

Bought contact lists go stale quickly in life sciences because people move between companies and projects. Start with account-level signals, then find the people.

Clinical trial registries

ClinicalTrials.gov and the EU's Clinical Trials Information System list sponsors, phases, conditions and sites. A sponsor moving a programme into phase 2 or 3 needs more sites, more monitoring, more manufacturing capacity and more data handling. That is a buying window for CROs, CDMOs and trial technology vendors.

Funding and partnering news

Biotech financing rounds and licensing deals create budget. A company that has just raised usually has a hiring plan and a list of external partners to appoint. Set alerts for your target therapy areas and regions.

Facility and hiring signals

New sites, expansions and job ads for roles you support (for example, a batch of QC analyst openings) point to growing workloads. Hiring for a head of a function you sell to often means a new decision-maker who will review suppliers.

Industry events

Life sciences trade fairs and partnering events remain important. Use exhibitor and speaker lists to build target accounts, then book meetings before the event rather than relying on walk-ups.

For more on building lists from public sources, see our guide to B2B leads from directories.

How to reach them: channel mix that fits pharma

Outbound email, written for one role at a time

Short, specific and relevant to the signal. Reference the trigger ("saw your phase 2 start in oncology"), name one problem that role owns, and ask one question. Avoid feature lists and anything that reads like a promotional claim about a medicine, because many pharma employees are trained to treat those carefully.

LinkedIn, from real people

Scientists and operations leads engage with peers, not logos. A founder or scientific lead posting useful, non-promotional content (method notes, regulatory updates, lessons from projects) builds recognition before outreach lands. Our LinkedIn content team builds this for technical founders.

Content that proves competence

White papers, technical webinars and case notes work well in pharma because buyers need evidence they can forward internally. Keep claims precise and sourced. See our webinar lead generation playbook for the format.

Events and partnering meetings

Face-to-face still matters for high-value services. Treat events as the middle of a sequence: outreach before, meetings during, follow-up within 48 hours.

Compliance: GDPR and industry codes

Two layers apply when you market to people who work in pharma.

Data protection. In the EU, B2B outreach to named individuals relies on a lawful basis, most often legitimate interest. Recital 47 of the GDPR notes that direct marketing may be regarded as a legitimate interest, but you still need a balancing test, a clear privacy notice and an easy opt-out. National e-privacy rules can add requirements for email, so check the country you're sending into. Our GDPR cold email playbook walks through the documentation.

Industry codes. Pharma companies follow industry codes on how they interact with healthcare professionals and how medicines are promoted. As a B2B supplier you're usually not promoting a medicine, but your buyers work inside those rules. Keep outreach factual, avoid anything that could look like an inducement, and never include claims about therapeutic outcomes.

This is practical guidance, not legal advice. Check your approach with counsel for the countries you target.

A 90-day pharma pipeline plan

1. Weeks 1 to 2: define the segment (therapy area, company stage, region) and the signals that indicate need.

2. Weeks 3 to 4: build 150 to 300 target accounts from registries, funding news and event lists. Map three to five roles per account.

3. Weeks 5 to 8: launch role-specific outbound in small batches, supported by founder or expert LinkedIn content.

4. Weeks 9 to 12: add a technical webinar or white paper for the accounts that engaged, and book meetings around one event.

5. Throughout: track account-level engagement, not just replies. In long cycles, a second person engaging at the same account matters more than one warm reply.

If you'd rather have this run for you, our lead generation service builds and operates the full system. The same account-signal approach works in manufacturing too.

FAQ

What is pharma lead generation?

It's the process B2B vendors use to find and start conversations with pharmaceutical and biotech companies that need their services or products, such as CROs, CDMOs, lab suppliers and software providers.

Where do I find leads in pharma and biotech?

Start with account signals: clinical trial registries, funding and licensing news, facility expansions and hiring. Then identify the functions that buy what you sell within those accounts.

Is cold email allowed when selling to pharma companies in the EU?

B2B outreach to named people can rely on legitimate interest under the GDPR if you document the balancing test, explain how you got the data and offer an easy opt-out. National e-privacy rules vary, so check each country you target.

How long is the pharma sales cycle?

For regulated services and systems it's usually measured in quarters rather than weeks, because supplier qualification, validation and procurement all take time. Plan lead generation for that cycle.

Which roles should I target first?

Usually the function that owns the problem you solve, such as clinical operations or process development, then procurement and quality once there's interest. Bring quality in early if your offer touches GxP processes.

About this guide

We are GROU, a B2B pipeline agency that runs lead generation, outbound, and LinkedIn content for clients across manufacturing, fintech, iGaming, software, pharma and professional services. Market figures in this guide come from EFPIA, and regulatory references link to their official sources.

Nothing in this guide is legal advice. For programmes in regulated markets, we align outreach and data handling with each client's legal and compliance team before launch.